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Abstract 
Whole exome sequencing and whole genome sequencing have become increasingly available in the 
research and clinical settings and are now also being offered by direct-to-consumer genetic testing 
companies. This offer can be perceived as amplifying the already identified concerns regarding 
adequacy of informed consent for both whole exome/genome sequencing and the 
direct-to-consumer (DTC) genetic testing context. We performed a qualitative content analysis of 
websites of four companies offering whole exome/genome sequencing DTC regarding the following 
elements of informed consent: pre-test counselling, benefits and risks, and incidental findings. The 
analysis revealed concerns including the potential lack of pre-test counselling in three of the 
companies studied; missing relevant information in the risks and benefits sections; and potentially 
misleading information for consumers. Regarding incidental findings, only one company, which 
provides opportunistic screening, provides basic information about their management. In 
conclusion, some of the information (and related practices) present on the companies’ webpages 
salient to the consent process are not adequate in reference to recommendations for informed 
consent for whole genome or exome sequencing in the clinical context. Requisite resources should 
be allocated to ensure that commercial companies are offering high throughput sequencing under 
responsible conditions, including an adequate consent process. 
Key words: whole genome sequencing, whole exome sequencing, direct-to-consumer genetic 
testing, consumer genomics, informed consent 
Introduction  
Whole exome and genome sequencing applications 
The relatively recent development of next generation sequencing (NGS) technologies has led 
to a significant decrease in the cost and time required to perform whole genome sequencing 
(WGS) and whole exome sequencing (WES) (i.e. the sequencing of only protein coding parts 
of the genome; for the purpose of this article, in which the high-through-put nature of NGS is 
most salient, both whole genome and whole exome sequencing may be denoted by ‘WGS’ or 
‘whole genome sequencing’). These technologies are more powerful and potentially cost-
effective than previous sequencing technologies and have brought a shift in testing approach 
from the traditional way of testing only one or a few specific genes to obtaining the 
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sequencing information from hundreds or even all the genetic variants in a genome (Wright et 
al. 2011).  
To date, the use of genomic sequencing approaches has proved to be useful in both the 
research context and clinical context; for instance, in providing molecular diagnoses for 
Mendelian disorders (Yang et al. 2013), for disorders with complex phenotypic presentations 
such as intellectual disabilities, or neurological  diseases (de Ligt et al. 2012; Martin et al. 
2014), potentially enabling targeted therapeutic strategies in some cases (Salleh et al. 2013). 
WGS can also be used for disease risk predictions (Heo et al. 2013), preconceptional carrier 
testing (Chrystoja and Diamandis 2014) and prenatal testing (Carss et al. 2014). In the short 
to medium-term future, other applications of WGS in health care may materialize, including 
for newborn screening (Solomon et al. 2012), tissue matching (Wright et al. 2011) or 
screening of embryos (Harper et al. 2013). Despite these technical possibilities, it is important 
to note that there are still concerns regarding the accuracy, interpretation of results, cost-
effectiveness, as well as ethical issues (Dewey et al. 2014).  
Given the relative novelty of NGS in the clinic and the resulting uncertainty related to 
implementation, the ethical concerns are numerous, and include but are not limited to issues 
related to the informed consent (IC) process, unsolicited findings management, opportunistic 
screening, secondary use of data, data management and storage, privacy and confidentiality, 
duty to re-contact patients (once new information arises), responsibility towards and 
communication with family members. All these outstanding issues currently, challenge the 
effective and responsible implementation of genome-based approaches in health management 
(Pinxten and Howard 2014) and need to be addressed. Herein we focus on the informed 
consent process in the more specific commercial context of direct-to-consumer high 
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throughput sequencing, which overlap with many of the concerns related to the clinical 
context. 
Direct-to-consumer genetic testing (DTC GT) companies  
Relatively recently, whole genome sequencing services have also been advertised and offered 
directly to consumers by some companies. These private, for-profit companies operate outside of 
the conventional public health care system and advertise genetic tests directly to consumers 
predominantly via the Internet. However, companies are increasingly requiring consumers to 
contact a health care professional (HCP) in order to obtain a test and/or the test results (Howard and 
Borry 2012). This type of genetic test which ‘are commissioned by the consumer but where a medical 
practitioner or health professional is involved in the provision of the service’ also fall in the scope of 
DTC genetic tests according to ‘A Common Framework of Principles’ on DTC genetic testing issued by 
the Human Genetics Commission (UK) (Human Genetics Commission 2010).  
The phenomenon of DTC GT, even before WGS was being offered in this context, has received a lot 
of attention regarding ethical issues, such as the questionable scientific validity and utility of the tests 
on offer (McGuire and Burke 2011), the adequacy of information provision and the informed consent 
procedure (Howard et al. 2010), the potential need for medical oversight and genetic counselling 
(Hogarth et al. 2008), the testing of children (Borry et al. 2009), the research activities conducted by 
DTC GT companies (Howard et al. 2010) and the potential burden on the health care system 
(McGuire and Burke 2011). The adequacy of legislations concerning the activities of DTC GT 
companies has also been discussed (Kalokairinou et al. 2014).  Considering the vast amount of 
genomic data obtained in WGS as well as difficulties in being able to properly assess or interpret each 
variant, one could consider that many, if not all, of the ethical, legal and social implications 
previously addressed at the DTC GT field are amplified in the context of companies offering WGS 
directly to consumers. As such, this particular type of DTC GT deserves further attention and study. 
Informed consent for WGS 
Informed consent is a key component of any responsible intervention in research involving humans or 
healthcare provision, including the offer of genetic testing (for health purposes), regardless of whether 
it is provided via a HCP in the conventional health care system or by a private for-profit company. 
Informed consent constitutes a voluntary permission given by a competent patient to have the test 
performed after (s)he has been duly informed about the procedure and purpose of the test, including 
the results it will generate, as well as the potential risks and benefits. The Additional Protocol to the 
Convention on Human Rights and Biomedicine concerning Genetic Testing for Health Purposes states 
that ‘A genetic test may only be carried out after the person concerned has given free and informed 
consent to it’. The document also outlines that the consent should be documented and it may be freely 
withdrawn at any time (Council of Europe 2008). Furthermore, the European Convention on Human 
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Rights and Biomedicine
a
, specifies in Article 5 that a person consenting to an intervention in the 
health field ‘shall beforehand be given appropriate information as to the purpose and nature of the 
intervention as well as on its consequences and risks.’ (Council of Europe 1997) Moreover, the 
importance of informed consent has been recognized in the recently accepted version of the Proposal 
for a Regulation of the European Parliament and of the Council on in vitro diagnostic medical 
devices
b
:  
 ‘Member States shall ensure that where a genetic test is used on individuals, in the context 
of healthcare as defined in Article 3(a) of Directive 2011/24/EU and for the medical purpose 
of diagnostics, improvement of treatments, predictive or prenatal testing, the individual 
being tested or, where applicable, his or her legally designated representative is provided 
with relevant information on the nature, the significance and the implications of the genetic 
test, as appropriate.’ (Article 4a) (Council of the European Union 2016) 
In the context of WGS, appropriate provision of information about the testing seems to be a 
particular challenge considering the complexity of the technology used, the volume of information 
generated, and the wide-ranging nature of findings. The entire sequence of the genome may provide 
an unprecedented amount of information of various clinical significance and predictive value, which 
may change with time (Wright et al. 2011). Furthermore, these results may have profound 
implications for the (psychological) health (care) and reproductive choices of a patient as well as his 
or her relatives. 
Given these challenges, various authors have proposed models for IC and attempted to determine 
the necessary elements of an adequate IC process for WGS (ACMG Board of Directors 2013; Ayuso et 
al. 2013; Bunnik et al. 2013,  2014; Jamal et al. 2013; Henderson et al. 2014). Ayuso et al. (2013) 
specifically analysed articles from the academic literature and guidelines from ‘societies’ concerning 
IC for genetic studies and WGS. The authors found a high level of consistency among the documents 
reviewed and proposed a minimum list of information that should be addressed in IC for WGS:  the 
scope of the test, a description of the test process, the possible benefits and risks, the availability of 
alternative tests, the voluntary nature of the test, the possibility of refusal, the future use of the 
samples and the data, the confidentiality of the outcomes and management of incidental findings 
                                                          
a
 The Convention on Human Rights and Biomedicine is only legally binding for those countries who have signed 
and ratified it (http://www.coe.int/en/web/conventions/full-list/-
/conventions/treaty/164/signatures?p_auth=GV537xJS). While, not all countries have done this (e.g. Germany, 
UK, Belgium, etc.), the Convention nonetheless, remains a very important moral benchmark and/or ethical 
framework in Biomedicine for all countries.  
b
 On 15 June 2016 the European Parliament and the Council of Europe have agreed on the draft of the 
proposal, which will undergo legal-linguistic review and will be adopted by the European Parliament and the 
Council of Europe, probably at the end of this year. The rules of the regulation will apply 5 years after its 
publication (http://ec.europa.eu/growth/tools-
databases/newsroom/cf/itemdetail.cfm?item_id=8863&lang=en). 
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(IF) (Ayuso et al. 2013). Moreover, the authors found that the majority of the documents they 
studied suggest that IC for whole genome sequencing should be given explicitly (Ayuso et al. 2013) 
(this is understood as being relevant in a context where WGS is only one of the tests being used for 
diagnosing a disorder, and so an explicit consent should be obtained specifically for the WGS). 
Jamal and co-authors (2013) also developed “core elements” of content and procedures for 
informed consent, data sharing, and results management for whole exome sequencing; even though 
conducted in a research context, the former overlap with core elements of informed consent 
identified by Ayuso et al. for the clinical context (Jamal et al. 2013). Furthermore, Jamal and co-
authors used the core elements to evaluate the practices and policies of 6 U.S. CLIA- certified labs 
offering clinical exome sequencing, including the presence of the suggested elements in informed 
consent forms and their readability. The analysis revealed that laboratory policies vary widely, 
indicating that developing standards for best practices among exome sequencing providers may be 
beneficial.  
Similarly, Henderson et al. (2014) (Henderson et al. 2014) have analysed IC forms used in nine NIH-
funded studies aiming to develop best practices for clinical applications of WGS. On the basis of the 
analysis the authors have proposed recommendations, which ‘can serve as a checklist to help 
identify gaps and resolve ambiguities in consent forms for sequencing’, and which are related to the 
issues outlined by Ayuso et al. (2013). For example, Henderson et al. suggest describing the meaning 
of positive, negative and uncertain results, outlining the role of CLIA (Clinical Laboratory 
Improvement Amendments) certification, and stating the likelihood of obtaining incidental findings. 
Furthermore, IC forms for WGS have also been analysed in the context of cancer studies. The 
examination of these IC forms has revealed the tendency for using samples in other, unspecified 
types of studies and sharing data with other researchers (Allen and Foulkes 2011).  
Furthermore, IC and the provision of information on company websites have been investigated in 
the context of DTC GT companies revealing the inadequacies of these practices (Howard et al. 2010; 
Lachance et al. 2010; Singleton et al. 2012). None of the studies, however, specifically addressed IC 
for WGS in the context of companies advertising or selling WGS directly to consumers. Therefore, 
herein we present an exploratory qualitative study of the information salient to the IC process, 
which is provided on websites of companies offering whole genome sequencing in the commercial 
direct-to-consumer context. In particular, we present information regarding the following elements 
salient to IC: 1) pre-test counselling, 2) expected benefits and possible risks; and 3) management of 
incidental findings. The information from company websites is then further contextualized and 
discussed against the backdrop of guidelines such as those from the Presidential Commission for the 
Study of Bioethical Issues (PCSBI) (Presidential Commission for the Study of Bioethical Issues 2013), 
recommendations for IC for WGS by Ayuso and colleagues (Ayuso et al. 2013), and the American 
College of Medical Genetics (ACMG) recommendations for the reporting of secondary findings 
(Green et al. 2013). 
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Methods 
This study is an explorative qualitative analysis of the informed consent information for whole 
genome and/or whole exome sequencing offered by DTC companies. We use a broad concept of 
DTC, including companies that offer genetic testing without a HCP, as well as those that aim 
marketing directly at consumers, while requiring a physician’s request to obtain the test. This 
approach is congruent with the scope of DTC GT given by the Human Genetics Commission, which 
included situations where ‘tests are commissioned by the consumer but where a medical practitioner 
or health professional is involved in the provision of the service’ (Human Genetics Commission 2010). 
The number and content of DTC genetic and genomic testing companies is often changing; this 
includes information about informed consentc. Against this background, and since no other 
academic article has addressed the specific issue of consent in the distinct context of WGS/WES, we 
opted for a non-exhaustive explorative qualitative study of a convenient and varied sample of 
company websites, which were selected between November 2013 and January 2014. Companies 
were identified through the academic literature (mostly via articles addressing DTC genetics), as well 
as with a general Internet search in English using the search engine Google and terms including 
‘genetic test’, ‘direct to consumer’, ‘whole genome sequencing’ and ‘whole exome sequencing’.  
Our qualitative analysis is focused on the website sections and documents available online that are 
presented by the companies with which consumers should agree and/or sign in order to undertake 
the test. Specifically, these are the IC documents, statement of consent, terms of service, terms and 
conditions, disclaimer and privacy policy (Table 1).  
For the qualitative content analysis of the relevant documents on the websites, we build on the 
study of Ayuso et al. (2013) and used the following elements of IC as the major codes: 1) pre-test 
counselling, 2) expected benefits and possible risks; and 3) management of incidental findings. These 
were underlined as being particularly important and relevant for IC in the context of WGS (Ayuso et 
al. 2013). The website documents were accessed in October 2014. The documents were perused for 
all material relevant to the codes above and were organized under these headings initially by one 
author; these initial results were reviewed by a second author and disagreements were resolved 
until both agreed on the adequate organization. Final tables including representative quotes were 
reviewed by all three authors. 
                                                          
c
 Indeed, some companies’ policies have already changed since our study, and as mentioned in the discussion, 
it is relevant that future studies return to these companies as well as include novel companies not addressed 
herein. For example, the version of Illumina’s consent form analysed herein is not available online any more. 
For a copy of the form please contact the corresponding author. 
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Results 
The DTC WGS companies identified and the studied website documents 
Four companies, Illumina, Gentle, Gene by Gene and Inneova, were identified for this study. They 
offer WES and/or WGS as well as provide different types/scope of data/results and analysis (e.g. 
carrier status, pharmacogenomics). The basic description and information regarding these four 
companies are outlined in Table 1.  
All the companies studied advertise their services directly to consumers on the Internet. However, 
some websites also contain sections dedicated to physicians, who are required to order the test, 
except for the company Gene By Gene’s offer of research and consumer testing, for which the 
company does not require a HCP. 
All companies’ websites analysed provide at least one document and/or a section on the 
webpage that needs to be agreed to or signed in order to undertake the test (Table 1). 
Three companies have documents on their website with ‘consent’ in the title; meanwhile, 
Gene By Gene only has a ‘Terms and Conditions’ section of the website and specifies that in 
case of ‘Clinical Genetic Testing’ the physician has to obtain IC from the consumer; however 
it does not state whether this includes a physical document that must be signed by the 
consumer: ‘Prior to placing an order, the ordering physician or genetic counselor is 
responsible for obtaining the informed consent from the patient whose sample is being sent 
for testing (…)’ (https://www.genebygene.com/pages/terms). Such a statement is not 
included in the section for ‘Research and Consumer testing’ in ‘Terms and Conditions’ of 
Gene by Gene (https://www.genebygene.com/pages/terms). 
The results of the content analysis regarding the following elements of IC: pre-test counselling, 
benefits and risks as well as incidental findings are presented below and shown in tables 2-4.  
Pre-test counselling  
Only Illumina (seemingly) requires pre-test counselling as a condition for undertaking the test. In the 
IC form a consumer has to sign the following statements:  
‘I have been offered the opportunity to ask questions and discuss with my healthcare 
provider the benefits and limitations of the test to be performed as indicated on the 
associated test request form. I have discussed with the medical practitioner ordering this test 
the reliability of positive or negative test results and the level of certainty that a positive test 
result for a given disease or condition serves as a predictor of that disease or condition.’ 
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(http://res.illumina.com/documents/clinical/forms/form-test-req-undiagnosed-disease.pdf) 
d  
Another company, Gentle, vaguely suggests some form of pre-test counselling to consumers in its IC 
section of the webpage: ‘If you still have unanswered questions, be sure to ask us or your physician 
before you agree to take the DNA test being offered by us.’ 
(https://www.gentlelabs.com/consent?content_only=true). No information about pre-test 
counselling was found on the studied websites’ sections of Gene by Gene and Inneova. 
Benefits and risks 
In the studied sections of the websites, all the companies provide general information about 
benefits and risks; however specific sections labelled ‘Benefits’ and ‘Risks’ are explicitly distinguished 
only in the IC document of Illumina and Gentle. More specific subthemes were identified within the 
subject Benefits and Risks (Table 3, in bold in columns 2 and 3); these were used to classify the 
benefits and risks and the labels were derived and modified from the classification outlined by Ayuso 
et al., 2013 (Ayuso et al. 2013).  
Three companies outline that the results may indicate disease risks and predispositions (Table 3). 
Moreover, Illumina and Gentle state that test results may help to make more informed healthcare 
choices; Gentle adds that the knowledge from the testing may empower persons to make ‘important 
life planning decisions’. Furthermore, Gentle outlines as a benefit, gaining knowledge about one’s 
carrier status, the possibility of adjusting drug therapy based on the genetic results, and gaining 
insight into one’s ancestry. This company also mentions as a benefit the possibility of participating in 
research studies conducted by the company.  
All the companies provide, at least, a general and/or short description of risks related to undertaking 
WGS (Table 3). The types of risks and concerns mentioned include the following: medical and 
physical risks, psychological risks, discrimination risks, and implications for family members. 
Implications for reproductive choices are mentioned only by one company, Inneova: ‘I realize the 
possible far-reaching implications of the information obtained through predictive genetics testing in 
affecting my life choices as well as those of my relatives, children, and unborn children’ 
(http://www.inneova.com/contenu.php?page=terms.php). 
Incidental findings and categorization of genetic information 
Only one of the analysed companies, Illumina, directly addresses the issue of incidental findings (IF) 
in its IC form (Table 4). The company refers to the first version of the American College of Medical 
Genetics’ (ACMG) recommendations for reporting of incidental findings (2013) (Green et al. 2013) 
and together with the results of Undiagnosed Disease Test provides an incidental findings report 
that may contain information on some of 57 variants unrelated to the indication for testing. 
                                                          
d At the time of submitting the article the link to this document was no longer functional. For a copy 
of the form please contact the corresponding author. 
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Meanwhile, in the consent form for Illumina’s Predisposition Screen test the possible findings are 
categorized (into: childhood onset and adult onset; subcategories: medically actionable, not 
medically actionable, cancer, neurologic conditions) and the consumer has the possibility to opt out 
of some of them. Although Gentle does not mention IF, the company does emphasize that 
customers can choose to exclude any condition from the analysis: ‘It is important to mention that 
you can choose to exclude any of the tests from the results before submitting your sample.’   
Discussion  
Informed consent in the context of DTC WGS companies 
The content analysis of DTC companies described herein has been conducted using some of the 
elements of IC for WGS in the clinical setting recommended by Ayuso et al. (2013) (Ayuso et al. 
2013). It should be noted that there are significant differences between the offers of WGS in a 
‘traditional’ clinical genetics context versus the commercial DTC setting, even if the latter involves a 
healthcare professional. As explained in the recent guideline issued by the Presidential Commission 
for the Study of Bioethical Issues (PCSBI): ‘Clinicians owe stringent fiduciary duties to patients, which 
entail an obligation to act in furtherance of the patient’s best interests. Non-clinician DTC providers 
have less stringent duties, including duties that might be limited or circumscribed by contract. 
Consumers should be made aware of these distinctions prior to consenting to undergo DTC testing.’ 
(p.103-104) (Presidential Commission for the Study of Bioethical Issues 2013). Indeed, in the context 
of DTC companies the contract describing the conditions of the service is usually stated in terms of 
service to which a consumer has to agree prior to buying the test. However, if the purpose of the 
test is health-related, signing a contract cannot fully replace the function of IC, which aims, among 
others, to provide understandable and balanced information about the test (Bunnik et al. 2014). The 
tests included in this study are advertised as having (to some extent) a health-related purpose or as 
clinical tests, therefore, the presence of adequate IC in the studied DTC companies appears to be 
advisable. 
Explicit informed consent and pre-test counselling 
Explicit informed consent, which is recommended by Ayuso et al. (2013) for clinical WGS, may be 
defined as one for which ‘Those who request consent must provide an explicit statement of the nature 
and purposes of a proposed course of action, its effects, risks and other features, to those whose 
consent is sought. Those who are asked to consent must show explicitly that they understand this 
information and agree to the proposal’ (Manson and O’Neill 2007). The process of explicit IC 
typically involves documents, signatures and formal statements (Manson and O’Neill 2007). 
Therefore, in this study we have focused on the documents or the section of the websites which the 
consumers have to agree to in order to be tested. However, in order to be genuinely informed consent 
should not be reduced to signing a document but rather through dialogue with a qualified HCP it 
should be ensured that the patient truly understands the information provided and is competent to 
make a choice (European Society of Human Genetics 2010).   
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Although all four companies provide some form of document addressing consent, only Illumina 
requires pre-test counselling understood as face-to-face consultation with a physician. In the other 
companies studied, most of the tests have to be ordered by the physician meaning that the 
consumer has to contact one in order to be tested. This, however, does not guarantee that adequate 
counselling takes place, given the concerns about the expertise in genetics and impartiality of the 
health care professionals (Howard and Borry 2012). Indeed, including a third party HCP in the 
process raises the question of who bears the (fundamental) ethical and legal responsibility for taking 
adequate consent? Of course, the HCP must adhere to the general medical code of conduct, but 
depending on her/his specialty, is (s)he aware of the specific guidelines for genetic testing?  
Another important result that brings attention to the involvement of healthcare professionals in 
testing is a lack of involvement of a physician in undertaking the consumer test in Gene By Gene 
company. Although ‘Terms and Conditions’ state that the services listed in ‘Research and Consumer 
Testing’ section ‘are not to be used to diagnose, prevent, or treat any condition or disease or to 
ascertain the state of health for any individual’ (https://www.genebygene.com/pages/terms), the 
description of the test suggests that it may provide health-related information: ‘Sequencing of the 
exome can help identify variants that may be the genetic cause of a wide range of traits and 
conditions.’ (https://www.genebygene.com/pages/research#). Therefore, the involvement of a 
genetics professional seems to also be advisable in the case of ‘Research and Consumer Testing’ of 
Gene By Gene, which could prevent misinterpretation of the results or unnecessary follow-up care.  
In addition, although the non-clinician DTC provider may have less stringent duties as stated by the 
PCSBI (Presidential Commission for the Study of Bioethical Issues 2013), the full role of a clinician in 
the DTC context still remains blurry. It is unknown to what extent physicians in the DTC context 
follow the same protocol as geneticist follow in the traditional health care system. 
Another aspect related to informed consent is the potentially low readership of the consent 
documents analysed herein. It has already been shown that most of the consumers read very little of 
the terms of service agreements (e.g. when purchasing software (Maronick 2014) or accessing Wi-
Fi). This may suggest that although the documents have the word ‘consent’ in the title and/or are 
aimed to be read and agreed to, the consumers are not acquainted with their content. This issue 
requires further analysis to assess the accessibility and readability of such documents. 
Information about benefits and risks  
The content analysis of the sections of companies’ websites reveals that the information regarding 
possible risks and benefits is scarce, general and omits some relevant elements such as description 
of the implications for the reproductive choices, which has been suggested by the recommendations 
for IC for WGS by Ayuso and colleagues (Ayuso et al. 2013).  Furthermore, some of the outlined 
information about benefits may be misleading such as regarding the possibility to participate in 
research studies (Table 3), which, in fact, does not necessarily benefit participants per se and is 
associated with various risks. Similarly, knowing the information about the carrier status is 
mentioned as a benefit in Gentle’s IC website section, but the implications for reproductive choices 
of having this knowledge are not described (Table 3). What is more, the information provided in the 
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documents that need to be signed differs from the information placed in other sections of the 
website, which seem to be more encouraging about the possible results. For example, in the ‘Why 
do a genetic test?’ section of the Inneova website they state that:  
‘The objective of predictive genetics testing from Inneova™ is to determine each person’s 
specific genetic features – and notably vulnerabilities – in order to allow highly-qualified 
practitioners in anti-aging and preventive medicine identify appropriate measures designed 
to counter-balance weaknesses and maintain good health, as well as help prevent the 
development of specific diseases or at least to delay their onset’ 
(http://www.inneova.com/tout.php?page=prev_why.php&menu=2).  
This may be misleading as consumers may not read the sections ‘Terms of Service’ or ‘Terms and 
Conditions’ (Howard et al. 2010), but rather take the decisions based on the information available on 
the main webpages. Finally, the content of the risks’ sections in the documents of Inneova and Gene 
By Gene could suggest that they were designed or written more in a way to protect the company 
from any liability rather than to explain and inform about potential disadvantages, e.g. ‘I agree that 
ICL (…) assumes no liability for any stress, strain, hardship, adverse medical condition, financial loss, 
or other circumstances that I may suffer as a result of the receipt or reference to any predictive 
genetics test results and/or interpretations thereof supplied to me by ICL’  
(http://www.inneova.com/contenu.php?page=terms.php). 
Some of the findings presented herein are in line with the results of the study of Singleton et al, 
2012 on informed choice in DTC-GT companies, which focuses on the websites of the DTC GT 
companies containing consumer-focused content excluding terms and conditions and privacy 
statements, therefore being to some extent complementary to this study. Singleton et al. found that 
the amount of information describing benefits outweighed risks statements and that the websites 
present conflicting information stating that the tests can help to prevent diseases, simultaneously 
giving information that the test cannot be used for diagnosis or treatment (Singleton et al. 2012). 
Similarly, Skirton et. al have found that misleading, conflicting or incomplete information was 
present on the websites of DTC companies offering non-invasive prenatal testing (Skirton et al. 
2015).  
Incidental/secondary findings 
The last, but not the least element of IC analysed in this study is the management of incidental 
findings. The term ‘incidental findings’ refers to ‘results that are outside the original purpose for 
which a test or procedure was conducted’ (Presidential Commission for the Study of Bioethical Issues 
2013), while secondary findings are results being sought deliberately because of the 
recommendations of an expert body as it has been defined by the PCSBI in the report on incidental 
and secondary findings (Presidential Commission for the Study of Bioethical Issues 2013). The issue 
of incidental and secondary findings appears particularly relevant in the context of WGS generating 
vast amount of data for analysis (Burke et al. 2013). Therefore, this topic has been discussed at great 
length and various expert societies have addressed it in recommendations. The PCSBI emphasizes 
the role of IC, and for the particular context of DTC companies suggests that the providers should 
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develop adequate procedures to manage IF and provide consumers with understandable materials 
explaining these procedures (Presidential Commission for Study of Bioethical Issues 2014). The 
American College of Medical Genetics (ACMG) also has issued recommendations for the reporting of 
secondary findings (although they use the term incidental findings, this is misleading since what they 
describe is opportunistic screening and not the strictly ‘unsolicited’ findings as described above) in 
WGS (Green et al. 2013). This policy statement of the ACMG suggests that secondary findings 
concerning 24 indicated conditions (related to 56 gene variants affecting function) should be sought 
and reported, however the patient may refuse the analysis of some of these genes if they are 
unrelated to the indication for testing, which should be done during the process of IC (Green et al. 
2013; ACMG Board of Directors 2014). In contrast, the recommendations of the European Society of 
Human Genetic which address incidental findings do not provide a specific list of reportable 
conditions but rather suggest narrowing the scope of the sequence analysis and developing 
guidelines and protocols (van El et al. 2013) in order to reduce the chances of encountering IF all 
together. Finally, some authors propose models of stratification of information derived from WGS 
including incidental/secondary findings which will help the discussion with, and the decision-making 
by the patient (Berg et al. 2011; Ayuso et al. 2013). 
Only one company out of the four studied addresses the issue of incidental/secondary findings and 
provides a report on IF complying with the recommendations of ACMG (Green et al. 2013) (hence 
also conducting opportunistic screening). However, the company does not indicate in the informed 
consent form whether the consumer has an opportunity to opt out of the analysis of some of the 
genes listed by the ACMG. Furthermore, regarding the primer issued by the PCSBI on IF (Presidential 
Commission for the Study of Bioethical Issues 2013) for DTC as well as the recent update of the 
recommendations for reporting secondary findings in genome-scale sequencing (ACMG Board of 
Directors 2014) the term ‘incidental findings’ used by Illumina is not consistent with the definition 
suggested by the PCSBI and should be replaced by the term ‘secondary findings’ in order to comply 
with the guidelines mentioned. Nevertheless, in the IC for Undiagnosed Disease Test Illumina seems 
to implement the recommendation included in the mentioned document for DTC providers, which 
are to prepare a plan for the management of incidental and secondary findings and to provide easily 
accessible information for consumers about this procedure. 
The IC form for Illumina’s Predisposition Screen test introduces categories of genetic information, 
which consumer may choose not to receive exercising his/her ‘right not to know’ some of the 
medical information. The categories of genetic information introduced by Illumina are to some 
extent in line to some to those suggested by Ayuso et al. (2013) as they arrange the conditions 
according to the time of onset and medical actionability facilitating the choice of consumers (Ayuso 
et al. 2013).  
Conclusions  
Concerning the elements studied herein the consent forms and documents on companies’ websites 
do not appear to fulfil the requirements for genuinely explicit and informed consent for WGS in the 
clinic as suggested by Ayuso et al. (2013). This highlights the present need to develop and implement 
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‘best practices’ for the DTC GT context with regard to IC and the provision of information about 
testing being offered. Moreover, the specific context of the commercial DTC GT companies which 
involve healthcare professionals could benefit from developing guidelines that specifically address 
this practice. 
This explorative qualitative study has some limitations. Since it considers a small and convenient 
sample of DTC WGS/WES companies’ and a subset of their written policies, it does not provide an 
exhaustive overview of all companies, their practices and associated ethical issues involved in the 
consent process. Indeed, we stress that the goal of this article is not meant to be an exhaustive, or 
generalizable (in a quantitative statistical way) analysis of DTC WGS companies, but rather a 
qualitative exploration of the activities that exist with respect to consent. Moreover, information 
provided on other pages of companies’ websites not analysed herein may also be relevant to IC 
process, which requires further investigation. Furthermore, other information such as that related to 
storage and future use of consumers’ samples and data pertain to IC and their presence in the 
process of IC in DTC companies also needs to be discussed. Finally, it is important to note that the 
nature of the DTC genetic and genomic testing market is very dynamic and the practices of 
companies are continuously evolving, thus it is important to monitor and continue to study and 
reflect on these activities. 
In conclusion, we acknowledge that informed consent is just one of the elements related to the 
ethical issues around WGS. Its adequacy may not resolve the other ethical issues related to the 
companies that offer WGS, however, as stakeholders in genetics, we should expect and aim to 
support and provide an adequately informed consent process in order to respect individuals in their 
health-related decisions..  
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Table 1 Basic information about the four companies selling WGS included in this study. The websites were accessed on 23 October 
2014. HCP = healthcare professional. 
Company name, 
country and website 
address 
 
Description of service 
Who can 
order the 
test
a
 
Sections of the 
websites studied 
 
 
Illumina, USA 
http://www.illumina.com/
clinical/illumina_clinical_la
boratory.html 
WGS: 
TruGenome Undiagnosed Disease Test –  with analysis and 
interpretation based on clinical indication; 
TruGenome Predisposition Screen –  with analysis and interpretation 
of 1,600 genes that have established associations to a set of 
conditions or diseases caused by single genes 
TruGenome Technical Sequence Data – raw data without interpretation 
 
 
 
 
 
only HCP  
 
 
Informed Consent 
(different form for 
each test) 
Gentle, Belgium 
https://gentlelabs.com/ 
WES - with analysis and interpretation of genetic variants related to 
carrier status, health risks and response to medications (please note 
that since this analysis, Gentle no longer offers DTC genetic testing
b
) 
 
only HCP 
Informed 
Consent, 
Terms of 
Service 
 
 
Gene By Gene, USA 
https://www.genebygene.
com/# 
 
Clinical testing 
WES - with analysis, search for the variant(s) of 
potential causative effect for the described 
phenotype 
 
only HCP 
 
 
 
Terms and 
Conditions 
Research and 
consumer testing 
 
WES and WGS - raw data or with analysis 
 
HCP and 
non-HCP 
 
Inneova, Canada 
http://www.inneova.com/ 
 
WGS – with analysis and interpretation concerning interaction of genes 
with ageing, nutritional and lifestyle choices and diseases 
 
 
only HCP 
Statement of 
consent, 
Disclaimer and 
privacy policy 
a
According to ‘A common framework of principles for DTC GT services’ issued by the Human Genetics Commission (UK)
14 
the 
type of genetic tests which ‘are commissioned by the consumer but where a medical practitioner or health professional is 
involved in the provision of the service’ also fall in the scope of DTC genetic tests. 
b
At the time of submitting this article Gentle stated on its company website “In order to focus all our efforts on the clinical 
diagnostics market, we are no longer selling the Gentle test to end users. If you are interested in our clinical interpretation 
services, please contact us.” (https://store.gentlelabs.com/) 
 
  
 
This article is protected by copyright. All rights reserved. 
 - 20 - 
 
Table 2 Information about the pre-test counselling for WGS offered by the studied 
companies. The information was accessed on 25 October 2014. 
Company name/type of 
service 
Pre-test counselling 
Illumina 
Not provided by the company but 
required for IC 
Gentle 
Not provided by the company but 
recommended in IC 
 
Gene By 
Gene 
Clinical testing 
 
No information 
Research and 
consumer testing 
Inneova No information 
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Table 3 Information about the possible benefits and risks of WGS included in the studied 
sections of the companies’ websites. Words in bold in ‘Benefits’ and ‘Risks’ columns are 
identified subthemes. The websites were accessed on 25 October 2014. 
 
Company Benefits Risks 
Illumina 'Your test results may help you and 
your physician make more informed 
choices about your healthcare. It is also 
possible that your test results will not 
provide any benefit.' 
Medical and/or physical risks: 'Side effects of 
having blood drawn are uncommon, but may 
include dizziness, fainting, soreness, bleeding, 
bruising, and, rarely, infection.' Psychological: 
'Your test results may reveal information about 
yourself, or your relatives, that you would 
rather not know. For example, you may learn 
information about genetic risks/predispositions 
to disease, including ones that might not be 
curable; ancestry; etc.' Implications for family 
members: 'In a trio or parent/child analysis, it 
may be uncovered that a family member is 
unrelated to the patient, such as in the case of 
adoption or non-paternity. It may not be 
possible to prevent learning such information 
through this test.' Discrimination risks: 
'Genetic information could be used as a basis of 
discrimination. (…) The laws may not protect 
against genetic discrimination in other 
circumstances such as when applying for life 
insurance or long-term disability insurance.' 
Company Benefits Risks 
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Gentle Knowledge about disease risks and 
predispositions: ' A person found to 
have an increased risk of disease might 
want to choose preventive or 
therapeutic medical treatments. 
Having this knowledge can empower a 
person and family members to make 
important life planning decisions, even 
if a cure is not available at the time of 
testing. (...) Knowing the genetic 
predisposition to these conditions 
allows you to take action, even before 
symptoms occur.' Information about 
carrier status: 'DNA-testing can inform 
a person about his/her carrier status 
for thousands of genetic conditions. 
Many genetic conditions are inherited 
in a recessive way. Being a carrier will 
usually not affect the health of the 
person him/herself, but might affect 
the health of future children. Screening 
your carrier status for diseases allows 
to check whether you might pass on 
severe conditions to your children.' 
More tailored drug therapy: 'Another 
benefit of DNA-testing is that you and 
your physician can make informed 
decisions on which medication is best 
for you.' Possibility to enroll in 
research studies: 'Having a specific 
diagnosis could qualify a person to 
enrol in research studies, which may 
lead to new treatments.' Insight into 
ancestry: 'DNA-testing can provide 
insight into a person’s ancestry. 
Examination of DNA variations can 
provide clues about where a person’s 
ancestors might have come from and 
about relationships between families.' 
Psychological: 'The greatest concern pertains 
to the way a DNA test result might change a 
person’s life. The decision to have DNA testing 
can be stressful. You may have emotional 
reactions to learning that you do- or do not— 
carry a gene change for a certain condition.' 
Implications for family members: 'Sometimes 
a test result may not only affect you, but also 
your family relationships. A person who decides 
to have DNA testing needs to consider whether 
to tell other family members. Sometimes the 
result for one family member can disclose 
information about the genetic makeup of other 
relatives, even if they have not been tested.' 
Discrimination risks: 'In some countries a DNA 
test result may also affect a person’s ability to 
obtain health, life, disability or long-term care 
insurance. It could also affect the ability to 
obtain or keep a job.' 
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Company Benefits Risks 
Gene By 
Gene 
Knowledge about disease risks and 
predispositions, information about 
carrier status, only for 'Clinical Genetic 
Testing': 'The purpose of clinical  
genetic testing is to evaluate the 
presence of the predisposition to 
genetic diseases, to assess the risk for 
developing a genetic disease, or to 
determine the carrier status of a known 
disease-causing mutation.' 
Psychological, discrimination risks for 'Clinical 
Genetic Testing' only: ' Gene By Gene, LTD. is 
not responsible for legal, material, social, 
psychological, or moral consequences related to 
the results of genetic testing.' Only for 
'Research and Consumer Testing': ' The 
customer is aware that some of the information 
received may be unexpected, and the customer 
takes responsibility for all possible 
consequences resulting from test data and 
sharing this data.' 
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Inneova Knowledge about disease risks and 
predispositions: ' I understand the 
basic concept of predictive genetics 
testing and how it may result in the 
discovery of genetic predispositions 
that could indicate an increased or 
decreased risk of developing certain 
medical conditions and diseases. I 
realize the possible far-reaching 
implications of the information 
obtained through predictive genetics 
testing in affecting my life choices as 
well as those of my relatives, children, 
and unborn children. (...) ICL is obliged 
to (...) provide me with predictive 
genetics test results, as well as an 
indicative, preliminary personalized 
report for each test performed based 
on statistical genetic research into the 
behaviour and interaction of genes 
with factors such as aging, nutritional 
and lifestyle choices, as well as various 
diseases and how they could affect my 
health and well being.’ 
Medical, psychological risks, implications for 
family members, discrimination risks:  'I 
realize the possible far-reaching implications of 
the information obtained through predictive 
genetics testing in affecting my life choices as 
well as those of my relatives, children, and 
unborn children. (…) I agree that ICL (together 
with its medical, scientific, and other service 
partners, subsidiaries and related business 
entities, legal advisors, agents, or appointees) 
assumes no liability for any stress, strain, 
hardship, adverse medical condition, financial 
loss, or other circumstances that I may suffer as 
a result of the receipt or reference to any 
predictive genetics test results and/or 
interpretations thereof supplied to me by ICL.' 
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Table 4 Information regarding the management of incidental findings resulting from WGS included 
in the studied sections of the companies’ websites. The websites were accessed on 25 October 
2014. 
Company, type of test Incidental findings 
Categorization of the 
genetic information 
Right not to 
know 
 
 
 
 
 
 
 
 
 
Illumina 
 
TruGenome 
Undiagnosed 
Disease Test 
Provides 'incidental 
findings' report of 
variants located in the 
genes recommended by 
ACMG 
 
 
No information 
 
 
No information 
 
 
 
TruGenome 
Predisposition 
Screen 
 
 
 
 
No information 
 
Yes, categories: childhood 
onset and adult onset; 
subcategories: medically 
actionable, not medically 
actionable, cancer, 
neurologic conditions 
 
 
Yes, option for 
excluding some 
of the categories 
from the test 
results 
TruGenome 
Technical 
Sequence Data 
 
Not applicable 
 
Not applicable 
 
Not applicable 
Gentle No information No information Yes 
Gene By Gene No information No information No information 
Inneova No information No information No information 
 
 
